BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Analysis

APAC Antibody-Drug Conjugates Past Phase 2, and Who Owns Them Now

Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...

November 05, 2026 | Analysis

China's 2026 Reimbursement Lists: 10 Drugs That Will Show Where Beijing Is Paying, and the Commercial List's Second Year

Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...

November 03, 2026 | Regulatory

APAC-Originated Obesity Drugs in the Clinic, Beyond Semaglutide

Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide and tirzepatide set the bench...

November 02, 2026 | Analysis

Japan's FY2027 Off-Year Drug Price Revision: 8 Numbers That Decide Who Pays

Japan's off-year drug price revision stopped being a question of whether some time ago. When the health and finance ministers closed the FY2026 budget roun...

October 29, 2026 | Analysis

17 APAC-Made Biosimilars Approved in the US or EU in 2026

Seventeen times in 2026, the US Food and Drug Administration or the European Commission cleared a biosimilar that was developed or made in Asia-Pacific. Ni...

October 28, 2026 | Analysis

Orphan Drug Incentives in 9 APAC Markets, Compared

Every January, regulatory affairs teams across Asia-Pacific rebuild the same spreadsheet. Which markets will designate this asset as an orphan? Which will ...

October 27, 2026 | Analysis

What Eight APAC Regulators Have Actually Published on AI in Drug Development

Ask a regulatory affairs lead in Tokyo, Seoul or Singapore what the rules are for using a machine learning model in a drug submission, and the honest answe...

October 22, 2026 | Analysis

FDA Warning Letters to APAC Drug Facilities in Fiscal 2026: The Full Ledger, Normalised

Every October, the same headline writes itself. India leads the count of US FDA warning letters to Asian drug plants, China follows, and the rest of the re...

October 21, 2026 | Analysis

How Long It Takes to Start a Clinical Trial in 8 APAC Markets, Timed

If you are building a 2027 trial budget this month, you are probably working from a spreadsheet with one row per country and a column headed "start-up". Mo...

October 19, 2026 | News

Semaglutide Generics, Six Months In: Every Launch in India, Every Price, and Where China Stands

AT A GLANCE 12 generic makers with a public launch in India, selling 20 brands between them Rs 1,290 lowest stated monthly price, for vials...

October 09, 2026 | Analysis

Every CAR-T Therapy Approved in Asia-Pacific, and What It Costs

Method in brief What counts. A CAR-T cell therapy approved on one of seven national registers: China's NMPA, Japan's PMDA and MHLW, Korea's MFDS, ...

October 08, 2026 | Analysis

From Academic Discovery to Biopharma Impact: Strengthening Southeast Asia’s Translation Pathway

Universities and public research institutes across the region are advancing research in cancer treatment, cell therapy, biologics and other emerging fields...

October 07, 2026 | Opinion | By Hajjerah TMK Hassan, Director, Discovery and Channels - ASEAN |Cytiva

12 Biotechs in Hong Kong's 18A Queue, and What Each Says It Will Spend the Money On

Every Hong Kong biotech applicant has to tell investors what it will do with the money it raises. On the evidence of the twelve 18A application proofs that...

October 07, 2026 | Analysis

Biotech Failures 2026: What Did Not Happen in APAC Biopharma

Approvals get counted, deals get ranked, listings get priced. The other half of the year, the programmes that stopped, the applications that came back, the...

October 02, 2026 | Analysis

Stay Connected